


**iScience, Volume 24**

**Supplemental information**

**Targeting myeloid-derived suppressor cells  
to attenuate vasculogenic mimicry and synergistically  
enhance the anti-tumor effect of PD-1 inhibitor**


**Yinan Li, Kailiang Qiao, Xiaoyun Zhang, Haoyang Liu, Heng Zhang, Zhiyang Li, Yanrong  
Liu, and Tao Sun**

**Figure S1. Apoptosis detection of MDSCs treated by DOX, Related to Figure 3.**



(A) Representative dot plots for apoptosis of MDSCs after DOX treatment. (B) Statistical analysis (Student t-test) of the apoptosis ratio of MDSCs. All statistical data are represented as mean  $\pm$  SEM. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .


**Figure S2. Doxycycline reduces the number of PMN-MDSCs in B16-F10 cell tumor-bearing model, Related to Figure 4.**



(A, C, and E) Dot plots of the proportion of PMN-MDSCs (CD11b<sup>+</sup>Ly6G<sup>+</sup>Ly6C<sup>low</sup>) and M-MDSCs (CD11b<sup>+</sup>Ly6G<sup>+</sup>Ly6C<sup>high</sup>) in bone marrow, spleen, and tumor cells from control and DOX-treated B16-F10 tumor-bearing mice (n = 3). (B, D, and F) Statistical analysis (Student t-test) of the ratio of MDSCs subsets. All statistical data are represented as mean  $\pm$  SEM. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

**Figure S3. Doxycycline reduces the number of PMN-MDSCs in 4T1 tumor-**

bearing model, Related to Figure5.



(A, C, and E) Dot plots of the proportion of PMN-MDSCs (CD11b<sup>+</sup>Ly6G<sup>+</sup>Ly6C<sup>low</sup>) and M-MDSCs (CD11b<sup>+</sup>Ly6G<sup>+</sup>Ly6C<sup>high</sup>) from control and DOX-treated 4T1 tumor-bearing mice (n = 3). (B, D, and F) Statistical analysis(Student t-test) of the ratio of MDSCs subsets in 4T1 tumor-bearing model. All statistical data are represented as mean ± SEM. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.